FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387381577> ?p ?o ?g. }

• W4387381577 endingPage "632" @default.
• W4387381577 startingPage "623" @default.
• W4387381577 abstract "The COronaVIrus Disease 2019 (COVID-19) is a common infectious disease characterized by hyperactivation of the immune response and the development of a “cytokine storm” upon progression. The aim of this study was to obtain additional information about the efficacy of the drug olokizumab in comparison with the Janus kinase inhibitor upadacitinib in real clinical practice in patients with mild to moderate COVID-19 and combined risk factors for disease progression. Methods. A single-center, non-interventional, prospective study was conducted in specialized day hospital patients (n = 125) who received therapy with olokizumab ( n = 62) (64 mg once intravenously) and the Janus kinase inhibitor upadacitinib ( n = 63) (orally, according to selected dosing regimen). The primary endpoint was the frequency of hospitalizations in the 24-hour hospital over the entire observation period. We also analyzed the frequencies of intensive care unit (ICU) transfer, prescription of respyratory therapy, use of “rescue” therapy (monoclonal antibodies/therapeutic proteins acting on interleukins (IL) and their receptors: IL-6 receptor inhibitors and Janus kinase inhibitors (baricitinib, tofacitinib, upadacitinib, etc.)), mortality, dynamics of laboratory and instrumental parameters, as well as frequency of negative and positive changes according to the clinical progression scale of the World Health Organization. Results. All study subjects showed rapid clinical improvement and recovery. Patients in both groups did not experience any negative clinical events, such as admission to a 24-hour hospital, prescription of respyratory therapy, use of “rescue” therapy, etc. Thus, the hyperinflammatory reaction and adverse clinical outcomes are effectively prevented by the timely use of both drugs. Those who received olokizumab had slightly higher levels of C-reactive protein (CRP) at baseline than those who received upadacitinib ( p < 0.001). The median CRP value returned to normal on the 4 th day in both groups. Patients treated with olokizumab showed a more pronounced change in CRP levels relative to baseline values. A similar trend was also established in body temperature. Conclusion. The study confirmed that early administration of olokizumab in patients with mild to moderate COVID-19 with several risk factors for the severe course is as effective a method of preemptive anti-inflammatory therapy as the use of Janus kinase inhibitors but more stronger suppression of markers and symptoms of intoxication." @default.
• W4387381577 created "2023-10-06" @default.
• W4387381577 creator A5004895643 @default.
• W4387381577 creator A5034550383 @default.
• W4387381577 creator A5038473161 @default.
• W4387381577 creator A5059254105 @default.
• W4387381577 creator A5060461449 @default.
• W4387381577 creator A5061720852 @default.
• W4387381577 creator A5063590940 @default.
• W4387381577 creator A5068561869 @default.
• W4387381577 creator A5078675502 @default.
• W4387381577 creator A5081566155 @default.
• W4387381577 creator A5086925244 @default.
• W4387381577 creator A5093011653 @default.
• W4387381577 date "2023-09-20" @default.
• W4387381577 modified "2023-10-12" @default.
• W4387381577 title "Efficacy of olokizumab in patients with mild or moderate COVID-19 and risk factors of progression" @default.
• W4387381577 cites W1803784511 @default.
• W4387381577 cites W3008090866 @default.
• W4387381577 cites W3110670148 @default.
• W4387381577 cites W3124895527 @default.
• W4387381577 cites W4206179867 @default.
• W4387381577 doi "https://doi.org/10.18093/0869-0189-2023-33-5-623-632" @default.
• W4387381577 hasPublicationYear "2023" @default.
• W4387381577 type Work @default.
• W4387381577 citedByCount "0" @default.
• W4387381577 crossrefType "journal-article" @default.
• W4387381577 hasAuthorship W4387381577A5004895643 @default.
• W4387381577 hasAuthorship W4387381577A5034550383 @default.
• W4387381577 hasAuthorship W4387381577A5038473161 @default.
• W4387381577 hasAuthorship W4387381577A5059254105 @default.
• W4387381577 hasAuthorship W4387381577A5060461449 @default.
• W4387381577 hasAuthorship W4387381577A5061720852 @default.
• W4387381577 hasAuthorship W4387381577A5063590940 @default.
• W4387381577 hasAuthorship W4387381577A5068561869 @default.
• W4387381577 hasAuthorship W4387381577A5078675502 @default.
• W4387381577 hasAuthorship W4387381577A5081566155 @default.
• W4387381577 hasAuthorship W4387381577A5086925244 @default.
• W4387381577 hasAuthorship W4387381577A5093011653 @default.
• W4387381577 hasBestOaLocation W43873815771 @default.
• W4387381577 hasConcept C112392421 @default.
• W4387381577 hasConcept C126322002 @default.
• W4387381577 hasConcept C143998085 @default.
• W4387381577 hasConcept C197934379 @default.
• W4387381577 hasConcept C203092338 @default.
• W4387381577 hasConcept C2776233030 @default.
• W4387381577 hasConcept C2776376669 @default.
• W4387381577 hasConcept C2778690821 @default.
• W4387381577 hasConcept C2781413609 @default.
• W4387381577 hasConcept C535046627 @default.
• W4387381577 hasConcept C71924100 @default.
• W4387381577 hasConcept C98274493 @default.
• W4387381577 hasConceptScore W4387381577C112392421 @default.
• W4387381577 hasConceptScore W4387381577C126322002 @default.
• W4387381577 hasConceptScore W4387381577C143998085 @default.
• W4387381577 hasConceptScore W4387381577C197934379 @default.
• W4387381577 hasConceptScore W4387381577C203092338 @default.
• W4387381577 hasConceptScore W4387381577C2776233030 @default.
• W4387381577 hasConceptScore W4387381577C2776376669 @default.
• W4387381577 hasConceptScore W4387381577C2778690821 @default.
• W4387381577 hasConceptScore W4387381577C2781413609 @default.
• W4387381577 hasConceptScore W4387381577C535046627 @default.
• W4387381577 hasConceptScore W4387381577C71924100 @default.
• W4387381577 hasConceptScore W4387381577C98274493 @default.
• W4387381577 hasIssue "5" @default.
• W4387381577 hasLocation W43873815771 @default.
• W4387381577 hasOpenAccess W4387381577 @default.
• W4387381577 hasPrimaryLocation W43873815771 @default.
• W4387381577 hasRelatedWork W2578491590 @default.
• W4387381577 hasRelatedWork W2605676125 @default.
• W4387381577 hasRelatedWork W2740125668 @default.
• W4387381577 hasRelatedWork W2752345645 @default.
• W4387381577 hasRelatedWork W2788336503 @default.
• W4387381577 hasRelatedWork W3134040084 @default.
• W4387381577 hasRelatedWork W4229690835 @default.
• W4387381577 hasRelatedWork W4236869562 @default.
• W4387381577 hasRelatedWork W4321168198 @default.
• W4387381577 hasRelatedWork W1778620981 @default.
• W4387381577 hasVolume "33" @default.
• W4387381577 isParatext "false" @default.
• W4387381577 isRetracted "false" @default.
• W4387381577 workType "article" @default.